Dr Reddy's Laboratories rose 3.45% to Rs 3,478 at 14:16 IST on BSE after consolidated net profit rose 7.73% to Rs 518.84 crore on 10.83% growth in total income to Rs 3882.97 crore in Q4 March 2015 over Q4 March 2014.
The Q4 result was announced during market hours today, 12 May 2015.
Meanwhile, the S&P BSE Sensex was down 585.36 points or 2.13% at 26,921.94.
On BSE, so far 98,000 shares were traded in the counter as against average daily volume of 27,388 shares in the past one quarter.
The stock hit high of Rs 3,492.65 and low of Rs 3,361.40 so far during the day. The stock had hit a record high of Rs 3,808.75 on 10 April 2015. The stock had hit a 52-week low of Rs 2,250 on 19 May 2014.
The stock had underperformed the market over the past one month till 11 May 2015, sliding 11.53% compared with Sensex's 4.75% fall. The scrip had, however, outperformed the market in past one quarter, jumping 6.58% as against Sensex's 3.6% fall.
The large-cap pharma firm has equity capital of Rs 85.19 crore. Face value per share is Rs 5.
Dr Reddy's Laboratories' Co-Chairman and CEO, GV Prasad said that the company is pleased with the progress on its financial and non-financial parameters, which it delivered despite currency volatility in some of its emerging market geographies.
Dr Reddy's Laboratories' board of directors recommended a final dividend of Rs 20 per share for the year ended 31 March 2015 (FY 2015).
Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Powered by Capital Market - Live News
